Innovation Theater

IT28T1: Dermatomyositis in Focus: What Do We Know about Immunoglobulin Therapy?

Industry Presenter(s)

• CC

  Christina Charles-Schoeman, MD;MS

  UCLA Medical Center
  Santa Monica, California, United States

  Disclosure information not submitted.
• 

  Iazsmin Bauer Ventura, MD, MS

  University of Chicago
  Chicago, Illinois, United States

  Disclosure information not submitted.

Please note: This session is not eligible for CME Credits through ACR.
This session will not be recorded for on-demand.

This session will begin with an overview of dermatomyositis, followed by the presentation of the broad mechanisms of action of immunoglobulins, offering insights into the underlying reasons for clinical effectiveness of immunoglobulins. Subsequently, real-world clinical cases will be discussed to illustrate practical approaches to the management of dermatomyositis in adults. The session will then transition to a detailed examination of phase 3 study data evaluating the efficacy and safety of immunoglobulin therapy to treat the disease. Special attention will be given to the influence of autoantibodies on clinical response. The session will conclude with an interactive Q&A part, during which faculty members will address audience questions and summarize key points relevant to clinical practice. Developed and offered by Octapharma. Not an official program of the ACR.

Agenda
1. Welcome and Introduction (Lazsmin Bauer-Ventura)
2. Understanding the Mechanisms of Action of Immunoglobulins to Improve their Clinical Use (Lazsmin Bauer-Ventura)
3. Exploring the Influence of Autoantibodies on Clinical Response (Christina Charles-Schoeman)
4. Q&A (All Faculty)
5. Closing Remarks (Christina Charles-Schoeman)